Orbit Discovery

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

Oxford, UK, 1st February 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having...

Orbit Discovery Awarded Innovate UK Grant to Expand High Throughput Cell-Based Functional Screening Platform Capabilities in Peptide Drug Discovery

Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., ('Orbit') a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UKís innovation agency. Totalling £472,000, the grant will facilitate the implementation of droplet-based microfluidics for cell-based...
Schrödinger Building, Heatley Rd, Oxford OX4 4GE

+44 (0) 1865 749234